Ciner, Aaron
Gourdin, Theodore
Davidson, Jeff
Parette, Mylisa
Walker, Susan J.
Fox, Todd E.
Jiang, Yixing http://orcid.org/0000-0002-0013-1807
Funding for this research was provided by:
U.S. Department of Defense (PC210475)
National Cancer Institute (CA1719835, CA208396, R44CA195793)
Cancer Center Support Grant (CA044579)
Article History
Received: 13 February 2023
Accepted: 5 September 2023
First Online: 22 September 2023
Declarations
:
: Penn State Research Foundation has licensed Ceramide nanoLiposomes (CNL) to Keystone Nano (KN) Inc. KN, who holds the IND for the phase I clinical trial, is developing CNL as Ceraxaâ„¢. Jeff Davidson is Chief Operating Officer of KN and Mylisa Parette previously served as Vice President of Research at KN. There are no other financial or non-financial conflicts of interest directly or indirectly related to this manuscript.